Aeterna Zentaris to Make Poster and Oral Presentations on Highly Selective Erk Inhibitor Compound, AEZS-131, at Major Cancer Conference in Boston

QUÉBEC CITY, Oct. 26 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), today announced that it will make a poster presentation, as well as an oral presentation on preclinical results for AEZS-131, a leading highly selective Erk inhibitor, which support its further evaluation as a potential anticancer compound in monotherapy or in combination with PI3K/Akt pathway inhibitors. Both presentations will be made during the Cambridge Healthtech Institute's 8th International "Discovery on Target" Conference, to be held November 2-4, 2010, in Boston, Massachusetts.

 

Poster presentation:
   
Title:
 
"A highly selective Erk-Inhibitor with anti-proliferative activity and the potential for combination therapy with modulators of the PI3K pathway ", M.Teifel, I. Seipelt, L. Blumenstein, S. Baasner, G. Mueller, B. Aicher, E. Guenther and M. Gerlach.
Presenter:  Michael Teifel, Ph.D., Senior Director - Head of Preclinical Development, Aeterna Zentaris
Poster group:   100
Date:   Tuesday, November 2, 2010, through Thursday, November 4, 2010
Location:  Exhibit Space, World Trade Center, Boston, MA
   
Oral presentation:
   
Title:    "A highly selective Erk-Inhibitor with anti-proliferative activity and the potential for combination therapy with modulators of the PI3K pathway "
Presenter:   Michael Teifel, Ph.D., Senior Director - Head of Preclinical Development, Aeterna Zentaris
Oral Presentation Track:   "The Challenge of Developing Kinase Inhibitors"
Date:    Thursday, November 4, 2010, at 11:25 a.m. (Eastern Time)
Location:   World Trade Center, Boston, MA

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, and endometrial cancer as well as multiple myeloma. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.
 

SOURCE AETERNA ZENTARIS INC.

CONTACT:

Investor Relations
Ginette Vallieres
InvestorRelations Coordinator
(418) 652-8525 ext. 265


Media Relations
Paul Burroughs
Director ofCommunications
(418) 652-8525 ext. 406
 

mailto:gvallieres@aezsinc.com gvallieres@aezsinc.com mailto:pburroughs@aezsinc.com pburroughs@aezsinc.com

Ticker Symbol: (NASDAQ-NMS:AEZS),(Toronto:AEZ)

Terms and conditions of use apply
Copyright © 2010 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: October 2010

View comments

Hide
(web4)